Press release - Understanding and tackling prostate and colorectal cancer through unlocking the cancer's DNA code

Press release - Understanding and tackling prostate and colorectal cancer through unlocking the cancer's DNA code

Kick-off meeting CTMM NGS-ProToCol project. First row: Wilbert van Workum, Guido Jenster (Principal Investigator, dressed in orange). F.l.t.r. second row: Remond Fijneman, Bauke Ylstra, Gerrit Meijer, Floor Pepers, David vd Meer and Mark de Jong.

27-02-2014 - With a large contribution of the Center for Translational Molecular Medicine (CTMM), a new Dutch consortium will study the relationship between DNA aberrations and the development of both prostate and colorectal tumours.

The project application has been filed by the Erasmus Medical Center, ServiceXS B.V. and the VU University Medical Center and will be coordinated by professor Guido Jenster (Erasmus MC). They have received funding of 1 million euros for this project called “NGS-ProToCol”.

Cancer and DNA

Cancer is a disease of the DNA, caused by changes in the genome of normal cells, resulting in cancer cells with the ability to continuously grow and to respond variably on anticancer treatments. In order to understand why normal cells become cancer cells and how we can identify and destroy them, the researchers in this project want to uncover all the DNA changes in a large set of individual tumors. Particularly for common tumor types such as prostate and colorectal cancers the researchers hope to make a serious impact and improve diagnosis, prognosis and treatment.

Recent developments in the area of genome sequencing (also called next-generation sequencing) make it possible to discover all mutations in a tumour in a single experiment. By analyzing the genome and transcriptome of multiple prostate and colorectal tumours, the researchers expect to discover and validate markers useful for finding tumors in an early stage and for predicting the aggressiveness of the disease. In addition, the genomic information will result in the identification of novel cancer proteins for which new therapeutic drugs can be designed.

Press release NGS-ProToCol (PDF)

Project page NGS-ProToCol

Output Booklets

If you want to see what 300 million euros of public-private partnership funding can achieve, take a look at the new set of output booklets that have been prepared for the individual CTMM projects.

Scientific breakthroughs, new products, patents, start-up companies, research infrastructures, PhD theses and academic papers, it's all there in black and white - proof that together we have achieved something truly remarkable and placed the Netherlands in a world leading position for translational medical research.

AIRFORCE - personalized chemotherapy against lung cancer

BIOCHIP - Diagnosing leukemia sub-types

Breast CARE - Predicting therapy response in breast cancer patients

DeCoDe - Early diagnosis of colorectal cancer

HIFU-CHEM - More chemo where it should be

MUSIS - Check removal of tumor tissue during surgery

PCMM - Limit over-diagnosis and over-treatment in prostate cancer

VOLTA - Remove tumors through local heating

Circulating Cells - investigating white blood cells and platelets for discriminating patients with increased risk of developing unstable plaques

COHFAR - how to detect and stop ventricular fibrillation by applying a synchronized electrical impulse to heart muscle

Eminence - developing multiple diagnostic technologies to detect neovascularization and stratifying patients

INCOAG - developing a new set of tests to estimate the risk of thrombosis

Parisk - how to predict risk of rupture of an individual plaque

Predicct - focusing on early diagnoses and treatment of Diabetes DM2

Triumph - identifying biomarkers for cardiac failure

LeARN - finding an early diagnosis of Alzheimer's Disease

AmpVacs - a new vaccine technology platform in the combat against conserved influenza A determinants

MARS - tools to provide rapid and accurate information about an individual patient suffering from sepsis

TRACER - patient-tailored treatment of Rheumatoid Arthritis

Health Technology Assessment (HTA)

TraIT - establishing an easy-to-access and easy-to-use infrastructure for sharing of research data, and set of tools for researchers to interact with and explore a unified translational medical research space

March 2018